EN DE
Watch Amplia Therapeutics Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Amplia Therapeutics Ltd (ATX) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Amplia Therapeutics Ltd stock A$0.07, price A$0.09, that is 18.6% below the price, quality 30 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU0000023822

AT Amplia Therapeutics Ltd logo Thin data Nov 10, 2026

Amplia Therapeutics Ltd

ATX · AU
Expensive, weak quality

Our calculation puts a fair price 19% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +156.3 %/yr in AUD)
Mixed vs. peers (5/10)
Revenue last quarter 9% below a year ago.
Fair value A$0.0708 · Overvalued
Quality 30/100
Loss-making · -160.9% net margin (TTM)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Amplia Therapeutics Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.3550 A$0.0490 Fair Value A$0.0708 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0490 – A$0.3550 · fair‑value band A$0.0569 – A$0.0846 · the A$0.0870 price screens above the A$0.0708 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Amplia Therapeutics in your weekly email

Every Wednesday you see whether Amplia Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Show moreShow less

Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.

The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Stock analysis

Amplia Therapeutics Ltd (ATX) currently trades at A$0.0870, while our estimate is A$0.0708, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0569 (bear) to A$0.0846 (bull), the price of A$0.0870 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Amplia Therapeutics Ltd reported revenue of A$3.8M in FY2025 versus A$1.5M in FY2021, a compound +25.3%/yr. Reported net income was −A$7.7M in FY2026.

Key figures

Market cap A$43.7M (≈ $30.0M) Micro · P/S ratio 9.32 · EPS (TTM) A$−0.0200 · Return on equity −25.5% · Return on assets (EBIT) −29.0% (5-year average) · Operating margin −186% · Revenue (TTM) A$4.8M · Revenue growth (YoY) −9.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 67% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −19%, ATX screens richer than that median.

Fair Value

Bear A$0.0569 Fair Value A$0.0708 Bull A$0.0846
Price A$0.0870 · Downside -18.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−15.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+156.3%
Start year 2020 (pandemic). Over 10 years: +62.0% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,600.4% (2020) → −172.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

ATX screens overvalued: fair value 19% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Amplia Therapeutics Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −18.6% · Above median
Profitability
Return on assets −18.6% · Above median
Net margin (12 months) −160.9% · Bottom 25%
Operating margin (12 months) −185.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −9.1% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.11× · Cheapest 25%
P/S (12 months) 9.11× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)9 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ATX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ATX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ATX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ATX
argenx SE ARGX $971.55 $908.40 −7% vs ATX
CSL Limited CSL A$201.68 A$181.40 −10% vs ATX
Moderna, Inc MRNA $250.83 $158.70 −37% vs ATX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ATX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ATX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ATX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amplia Therapeutics Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Amplia Therapeutics Ltd Fair Value". https://www.fairvalue-calculator.com/stock/ATX.AU

Frequently asked questions

Is Amplia Therapeutics Ltd (ATX) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0708 versus a price of A$0.0870, about 19% lower (overvalued).
What is the fair value of ATX?
Our estimate for Amplia Therapeutics Ltd is A$0.0708 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0870.
What is the quality score of ATX?
Amplia Therapeutics Ltd has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amplia Therapeutics Ltd (ATX)?
Our calculated price target is the estimate of A$0.0708 (as of Nov 10, 2026). Cautious scenario A$0.0569, optimistic scenario A$0.0846. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Amplia Therapeutics Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.0708, about 19% lower versus a price of A$0.0870 (overvalued). Cautious scenario A$0.0569, optimistic scenario A$0.0846. The calculation is refreshed regularly with new filings.
What is the revenue of Amplia Therapeutics Ltd (ATX)?
Amplia Therapeutics Ltd reported trailing-twelve-month revenue of about A$4.8M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Amplia Therapeutics Ltd (ATX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amplia Therapeutics Ltd it is A$0.0708 per share (as of Nov 10, 2026), against a price of A$0.0870.
Is Amplia Therapeutics Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ATX trades above its calculated fair value: price A$0.0870, fair value A$0.0708, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATX?
No. The price is what the market pays today (A$0.0870); the fair value is what the company's own numbers justify (A$0.0708). For Amplia Therapeutics Ltd the two are A$0.0162 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amplia Therapeutics Ltd worth?
The market values Amplia Therapeutics Ltd at about A$43.7M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0870; our models calculate a fair value of A$0.0708 per share.
What do the bullish and bearish scenarios say about ATX?
Our models span a range for Amplia Therapeutics Ltd: cautious scenario A$0.0569, base A$0.0708, optimistic A$0.0846 per share (as of Nov 10, 2026, price A$0.0870). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Amplia Therapeutics Ltd (ATX)?
Balance-sheet figures for Amplia Therapeutics Ltd (as of Nov 10, 2026): return on equity −25.5%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is ATX from its 52-week high?
Amplia Therapeutics Ltd trades at A$0.0870, about 67% below its 52-week high of A$0.2650 and 12% above the low of A$0.0780 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0708 is for.
Which stocks are comparable to Amplia Therapeutics Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amplia Therapeutics Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0870, calculated fair value A$0.0708 (−19%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Amplia Therapeutics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amplia Therapeutics Ltd (ATX)?
The closing price on Nov 11, 2026 was A$0.0870. Our estimate is A$0.0708, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amplia Therapeutics Ltd right now?
The price sits above even our optimistic bull case (A$0.0846). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Amplia Therapeutics Ltd

How large is the market capitalisation of Amplia Therapeutics Ltd (ATX)?
The market capitalisation of Amplia Therapeutics Ltd is A$43.7M (≈ $30.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amplia Therapeutics Ltd (ATX)?
The price-to-sales ratio of Amplia Therapeutics Ltd is 9.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amplia Therapeutics Ltd (ATX)?
Earnings per share at Amplia Therapeutics Ltd are A$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Amplia Therapeutics Ltd (ATX)?
The return on equity (ROE) of Amplia Therapeutics Ltd is −25.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amplia Therapeutics Ltd (ATX)?
On an EBIT basis the return on assets of Amplia Therapeutics Ltd is −29.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amplia Therapeutics Ltd (ATX)?
The operating margin of Amplia Therapeutics Ltd is −186% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amplia Therapeutics Ltd (ATX)?
Revenue at Amplia Therapeutics Ltd is growing −9.1% versus a year earlier (3y avg +24.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Amplia Therapeutics Ltd (ATX) generate?
The free cash flow of Amplia Therapeutics Ltd is −A$8.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Amplia Therapeutics Ltd (ATX) hold?
Amplia Therapeutics Ltd holds more cash than debt, A$27.5M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Amplia Therapeutics Ltd in the live analysis

One click puts Amplia Therapeutics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.